These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33968058)

  • 1. Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?
    García-Ríos E; Nuévalos M; Mancebo FJ; Pérez-Romero P
    Front Immunol; 2021; 12():657144. PubMed ID: 33968058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial.
    Smith C; Beagley L; Rehan S; Neller MA; Crooks P; Solomon M; Holmes-Liew CL; Holmes M; McKenzie SC; Hopkins P; Campbell S; Francis RS; Chambers DC; Khanna R
    Clin Infect Dis; 2019 Feb; 68(4):632-640. PubMed ID: 29982441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
    Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
    Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.
    Brestrich G; Zwinger S; Fischer A; Schmück M; Röhmhild A; Hammer MH; Kurtz A; Uharek L; Knosalla C; Lehmkuhl H; Volk HD; Reinke P
    Am J Transplant; 2009 Jul; 9(7):1679-84. PubMed ID: 19459791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
    Molina-Ortega A; Martín-Gandul C; Mena-Romo JD; Rodríguez-Hernández MJ; Suñer M; Bernal C; Sánchez M; Sánchez-Céspedes J; Pérez Romero P; Cordero E
    Clin Microbiol Infect; 2019 Jun; 25(6):753-758. PubMed ID: 30292792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
    Haidar G; Boeckh M; Singh N
    J Infect Dis; 2020 Mar; 221(Suppl 1):S23-S31. PubMed ID: 32134486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients.
    Amini L; Vollmer T; Wendering DJ; Jurisch A; Landwehr-Kenzel S; Otto NM; Jürchott K; Volk HD; Reinke P; Schmueck-Henneresse M
    Front Immunol; 2019; 10():1148. PubMed ID: 31191530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
    Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
    Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus- and cytomegalovirus-specific adoptive T-cell therapy in the context of hematologic cell transplant or HIV infection - A single-center experience.
    Obermaier B; Braun C; Hensen L; Ahmad O; Faul C; Lang P; Bethge W; Lengerke C; Vogel W
    Transpl Infect Dis; 2024 Aug; 26(4):e14296. PubMed ID: 38830809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
    Lemmermann NA; Reddehase MJ
    Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus.
    Pei XY; Zhao XY; Chang YJ; Liu J; Xu LP; Wang Y; Zhang XH; Han W; Chen YH; Huang XJ
    J Infect Dis; 2017 Nov; 216(8):945-956. PubMed ID: 29029297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.
    Feuchtinger T; Opherk K; Bethge WA; Topp MS; Schuster FR; Weissinger EM; Mohty M; Or R; Maschan M; Schumm M; Hamprecht K; Handgretinger R; Lang P; Einsele H
    Blood; 2010 Nov; 116(20):4360-7. PubMed ID: 20625005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients.
    Rowshani AT; Bemelman FJ; van Leeuwen EM; van Lier RA; ten Berge IJ
    Transplantation; 2005 Feb; 79(4):381-6. PubMed ID: 15729162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
    Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
    J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro.
    Greenberg PD; Reusser P; Goodrich JM; Riddell SR
    Ann N Y Acad Sci; 1991 Dec; 636():184-95. PubMed ID: 1665321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
    Walter EA; Greenberg PD; Gilbert MJ; Finch RJ; Watanabe KS; Thomas ED; Riddell SR
    N Engl J Med; 1995 Oct; 333(16):1038-44. PubMed ID: 7675046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
    Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
    Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
    Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation].
    Xu Z; Huang X; Sun Y; Wang F; Yan C; Zhang X; Han W; Chen Y; Wang J; Chen H; Wang Y; Zhang Y; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):101-5. PubMed ID: 25907838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials with CMV-specific T cells.
    Peggs KS; Mackinnon S
    Cytotherapy; 2002; 4(1):21-8. PubMed ID: 11953038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.